Results out today confirm that the drug donanemab, hailed as a turning point in the fight against Alzheimer’s, slows cognitive decline by about a third.
The antibody treatment helps in the early stages of the disease.
It works in Alzheimer’s disease, not in other types of dementia, such as vascular dementia.
That is because it is designed to clear away one of the key features of Alzheimer’s disease – a substance called amyloid that builds up in the spaces between brain cells.
Please subscribe here: http://bit.ly/1rbfUog
#Dementia #Alzheimers #BBCNews